CREATING DISRUPTIVE VENTURES THROUGH FEARLESS INNOVATION



CCRM's Venture by Design program is built upon our team's mastery as inventors, scientists, entrepreneurs and manufacturing experts, spanning the entire commercialization spectrum for advanced therapies.

Venture by Design is our problem-first company creation stream, aiming to address major unmet clinical needs with disruptive therapy concepts developed through a new innovation model.

The concepts are created by our scientist-entrepreneurs, enabled by technology solutions accessed through our established global networks, evaluated by our mentors, and realized as impactful ventures by our company creation experts.

A BOLD, NEW MODEL FOR INNOVATION IN ADVANCED THERAPIES



Screen Opportunity Areas

- ▶ Scope market gaps and unmet clinical needs
- Utilize our proprietary needs assessment rubric
- Exploit our flexible model to tailor scope



Ideate on Solutions and Seek Technology Components

- ldeation on disruptive *de novo* solutions
- Access to enabling technologies via 200+ institutions
- Internal de-risking and feasibility testing including wet diligence



Proprietary Innovation Model Powered by Custom AI Co-pilot

- ▶ Deep in-house sector expertise in advanced therapies
- ► Al co-pilot with domain expertise
- ► Accelerated diligence, pipeline build and predictive modelling



Resources

- ▶ Seasoned external committee of clinicians, scientists, industry leaders and investors
- ► Seed/pre-seed funding and access to investor network
- Infrastructure and trained staff
- >60 customers as potential future receptors

LAUNCHING INNOVATIONS INTO THE MARKET

Why work with us

CCRM transforms scientific discoveries into impactful regenerative medicine ventures.

Through its unmatched all-in-one commercialization model, CCRM provides value to academics by streamlining the path to market, and offers investors and partners access to high-potential de-risked opportunities, infrastructure and global networks.




TRANSFORMING ACADEMIC DISCOVERIES INTO MARKET-READY VENTURES

CCRM actively sources innovative technologies through its expansive global network of partnering institutions under our technology-first company creation stream. With world-leading sector expertise and a commercialization track record, CCRM moves academic inventions to market through a proven process.

BUILT-IN PATH TO SCALABILITY

- ▶ Team: Trained staff of 240+
- >60% with advanced degrees
- ▶ Global networks: Academic, industry and investors
- Access to complementary IP through 200+ institutions
- Global hubs expand footprint to three continents
- ► Capital: Fully-funded de-risking, pre-seed/seed funding
- 18 portfolio companies (2 exits)
- 3 incorporated companies
- CA >\$1.2 B+ raised to date
- ► Scalability: Established infrastructure and expertise
- In-house R&D for wet diligence
- 30,000 sq. ft. in-house process and analytical development and GMP facility
- Access to 115,000 sq. ft. CDMO subsidiary, OmniaBio Inc.



- ► SEED CAPITAL
- ▶ INVESTOR NETWORK
- ▶ PREFERRED RATES



- ▶ OFFICE SPACE
- ▶ PROCESS DEVELOPMENT
- ▶ GMP FACILITY ACCESS



- ► TECHNICAL EXPERTISE
- ▶ IP SUPPORT
- ▶ FINANCE & BACK-OFFICE SUPPORT

PEOPLE

STRATEGIC PARTNERS & INVESTORS

NON-DILUTIVE

FUNDING

LAUNCH OF NEW ADVANCED THERAPY VENTURE

Connect with us:

concepts@ccrm.ca

ccrm.ca

